Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 2/20 | 0.41 |
| ▸ | PIEZO1 | Q92508 | 1/20 | 0.38 |
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.38 |
| ▸ | RORC | P51449 | 5/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
| ▸ | TYK2 | P29597 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29393476 | 1.00 | P2RX7 (0.41) | P2RX7PIEZO1TAAR1RORCPTGS2 | |
| SCHEMBL954085 | 0.85 | TAAR1 (0.43) | P2RX7TAAR1L3MBTL1SMN1; SMN2 | |
| SCHEMBL27955417 | 0.85 | TAAR1 (0.39) | P2RX7PIEZO1TAAR1RORCPTGS2 | |
| SCHEMBL12812210 | 0.80 | TAAR1 (0.41) | P2RX7PIEZO1TAAR1RORCPTGS2 | |
| SCHEMBL15173346 | 0.80 | TAAR1 (0.47) | P2RX7PIEZO1TAAR1RORCPTGS2 | |
| SCHEMBL16939396 | 0.80 | P2RX7 (0.41) | P2RX7PIEZO1TAAR1RORCPTGS2 | |
| Bromide SCHEMBL25372781 | 0.78 | HSD11B1 (0.38) | P2RX7PIEZO1TAAR1RORCPTGS2 | |
| SCHEMBL9770 | 0.78 | TAAR1 (0.50) | TAAR1AKR1B1GAASMN1; SMN2 | |
| SCHEMBL29395789 | 0.78 | SLC6A2 (0.40) | P2RX7TAAR1PTGS2HSD11B1SMN1; SMN2 | |
| SCHEMBL11520584 | 0.78 | TAAR1 (0.39) | P2RX7PIEZO1TAAR1RORCHSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12435078-B2 | Pyridazinones and methods of use thereof | GFB (ABC), LLC (US) | 2025-10-07 | — | — | US | disclosed |
| US-20250228865-A1 | COMPOUNDS FOR ENHANCING READ THROUGH OF GENES CONTAINING PREMATURE TERMINATION CODONS AND METHODS FOR MAKING AND USING THE SAME | SANOFI US SERVICES INC. (US) | 2025-07-17 | — | — | US | disclosed |
| US-20240002344-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR HISTONE LYSINE DEMETHYLASE INHIBITION | FIBROGEN, INC. | 2024-01-04 | — | — | US | disclosed |
| EP-4204400-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR HISTONE LYSINE DEMETHYLASE INHIBITION | Fibrogen, Inc. (US) | 2023-07-05 | — | — | EP | disclosed |
| US-20230203028-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | GFB (ABC), LLC | 2023-06-29 | — | — | US | disclosed |
| US-20230203028-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | GFB (ABC), LLC | 2023-06-29 | — | — | US | disclosed |
| CN-116348450-A | Compounds, compositions and methods for histone lysine demethylase inhibition | 菲布罗根有限公司 | 2023-06-27 | — | — | CN | disclosed |
| EP-3256450-B1 | SUBSTITUTED PYRAZOLE COMPOUNDS AS ROR-GAMMA-T INHIBITORS AND USES THEREOF | MERCK SHARP & DOHME (US) | 2020-12-02 | — | — | EP | disclosed |
| EP-3256450-B1 | SUBSTITUTED PYRAZOLE COMPOUNDS AS ROR-GAMMA-T INHIBITORS AND USES THEREOF | MERCK SHARP & DOHME (US) | 2020-12-02 | — | — | EP | disclosed |
| EP-3684364-A2 | PYRIDAZINONES AND METHODS OF USE THEREOF | Goldfinch Bio, Inc. (US) | 2020-07-29 | — | — | EP | disclosed |
| EP-2884977-A2 | N-ALKYLATED INDOLE AND INDAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF | Merck Sharp & Dohme Corp. (US) | 2015-06-24 | — | — | EP | disclosed |
| EP-2757103-A1 | PYRROLIDINE-3-YLACETIC ACID DERIVATIVE | Eisai R&D Management Co., Ltd. (JP) | 2014-07-23 | — | — | EP | disclosed |
| WO-2014028591-A2 | N-ALKYLATED INDOLE AND INDAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF | MERCK SHARP & DOHME CORP. (US) | 2014-02-20 | — | — | WO | disclosed |
| US-8476301-B2 | Pyrrolidin-3-ylacetic acid derivative | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-07-02 | — | — | US | disclosed |
| US-8399436-B2 | N-pyrazolyl carboxamides as CRAC channel inhibitors | GLAXO GROUP LIMITED (GB) | 2013-03-19 | — | — | US | disclosed |
| US-20130065925-A1 | PYRROLIDIN-3-YLACETIC ACID DERIVATIVE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-03-14 | — | — | US | disclosed |
| US-20120053150-A1 | N-PYRAZOLYL CARBOXAMIDES AS CRAC CHANNEL INIHIBITORS | GLAXO GROUP LIMITED (GB) | 2012-03-01 | — | — | US | disclosed |
| EP-2421835-A1 | N-PYRAZOLYL CARBOXAMIDES AS CRAC CHANNEL INHIBITORS | Glaxo Group Limited (GB) | 2012-02-29 | — | — | EP | disclosed |
| WO-2010122089-A1 | N-PYRAZOLYL CARBOXAMIDES AS CRAC CHANNEL INHIBITORS | GLAXO GROUP LIMITED (GB) | 2010-10-28 | — | — | WO | disclosed |
| US-20100273744-A1 | COMPOUNDS | GORE PAUL MARTIN | 2010-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203028-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | PDXK, ATP6V1B1, REN | P2RX7 270/4885PIEZO1 4422/4885TAAR1 951/4885 |
| US-20120053150-A1 | N-PYRAZOLYL CARBOXAMIDES AS CRAC CHANNEL INIHIBITORS | ORAI1, TRPV1, CACNA1E | P2RX7 55/4885PIEZO1 260/4885TAAR1 1015/4885 |
| US-12435078-B2 | Pyridazinones and methods of use thereof | PDXK, ATP6V1B1, REN | P2RX7 270/4885PIEZO1 4422/4885TAAR1 951/4885 |
| US-20250228865-A1 | COMPOUNDS FOR ENHANCING READ THROUGH OF GENES CONTAINING PREMATURE TERMINATION CODONS AND METHODS FOR MAKING AND USING THE SAME | UPF1, NUDT21, RNGTT | P2RX7 3543/4885PIEZO1 4638/4885TAAR1 3612/4885 |
| US-20130065925-A1 | PYRROLIDIN-3-YLACETIC ACID DERIVATIVE | CX3CR1, CCR2, CCL2 | P2RX7 1156/4885PIEZO1 1912/4885TAAR1 681/4885 |
| US-20240002344-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR HISTONE LYSINE DEMETHYLASE INHIBITION | KDM5C, KDM5B, KDM5A | P2RX7 4287/4885PIEZO1 4868/4885TAAR1 4600/4885 |
| US-20100273744-A1 | COMPOUNDS | LTC4S, HRH4, HRH2 | P2RX7 573/4885PIEZO1 2566/4885TAAR1 1718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.